Novartis Ag (NVS) Intangibles (2009 - 2026)
Novartis Ag (NVS) posted Intangibles of $42.1 billion for Q2 2026, up 272.34% sequentially from $11.3 billion in Q1 2026, and up 43.89% YoY from $29.2 billion in Q2 2025.
Novartis Ag (NVS) Intangibles (2009 - 2026) Analysis & Trends
Novartis Ag has reported Intangibles for 18 years, with the latest figure at $42.1 billion in Q2 2026.
- Quarterly Intangibles rose 43.89% year-over-year to $42.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $42.1 billion (up 43.89% YoY) and the FY2025 annual result came in at $29.4 billion, up 9.27% from the prior year.
- Intangibles improved to $42.1 billion in Q2 2026 per NVS's latest filing, from $11.3 billion in the prior quarter.
- Over five years, Intangibles peaked at $69.7 billion in Q4 2022 and troughed at $11.3 billion in Q1 2026.
- A 5-year average of $35.6 billion and a median of $29.3 billion in 2025 frame the typical range for Intangibles.
- The sharpest annual moves came in 2024 and 2026: Intangibles slumped 53.85% in 2024, then soared 43.89% in 2026.
- Over 5 years, Intangibles stood at $69.7 billion in 2022, then decreased by 16.31% to $58.3 billion in 2023, then plunged by 53.85% to $26.9 billion in 2024, then grew by 9.27% to $29.4 billion in 2025, then surged by 43.06% to $42.1 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $42.1 billion, $11.3 billion, and $29.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.07 Bn |
| Mar 31, 2026 | 11.30 Bn |
| Dec 31, 2025 | 29.41 Bn |
| Jun 30, 2025 | 29.24 Bn |
| Dec 31, 2024 | 26.92 Bn |
| Jun 30, 2024 | 27.78 Bn |
| Dec 31, 2023 | 58.32 Bn |
| Jun 30, 2023 | 28.00 Bn |
| Dec 31, 2022 | 69.68 Bn |
| Jun 30, 2022 | 33.37 Bn |
| Dec 31, 2021 | 68.21 Bn |
| Jun 30, 2021 | 34.82 Bn |
| Dec 31, 2020 | 67.73 Bn |
| Sep 30, 2020 | 218.00 Mn |
| Jun 30, 2020 | 36.67 Bn |
| Dec 31, 2019 | 53.42 Bn |
| Jun 30, 2019 | 27.22 Bn |
| Mar 31, 2019 | 505.00 Mn |
| Dec 31, 2018 | 69.03 Bn |
| Sep 30, 2018 | 507.00 Mn |